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CXCR6 marks a novel subset of 
T-betloEomeshi natural killer cells 
residing in human liver
Kerstin A. Stegmann1, Francis Robertson2, Navjyot Hansi3, Upkar Gill3, Celeste Pallant1, 
Theodoros Christophides1, Laura J. Pallett1, Dimitra Peppa1, Claire Dunn1, Giuseppe Fusai2, 
Victoria Male1, Brian R. Davidson2, Patrick Kennedy3 & Mala K. Maini1
Natural killer cells (NK) are highly enriched in the human liver, where they can regulate immunity 
and immunopathology. We probed them for a liver-resident subset, distinct from conventional bone-
marrow-derived NK. CXCR6+ NK were strikingly enriched in healthy and diseased liver compared 
to blood (p < 0.0001). Human hepatic CXCR6+ NK had an immature phenotype (predominantly 
CD56brightCD16−CD57−), and expressed the tissue-residency marker CD69. CXCR6+ NK produced 
fewer cytotoxic mediators and pro-inflammatory cytokines than the non-liver-specific CXCR6− fraction. 
Instead CXCR6+ NK could upregulate TRAIL, a key death ligand in hepatitis pathogenesis. CXCR6 
demarcated liver NK into two transcriptionally distinct populations: T-bethiEomeslo(CXCR6−) and 
T-betloEomeshi(CXCR6+); the latter was virtually absent in the periphery. The small circulating CXCR6+ 
subset was predominantly T-bethiEomeslo, suggesting its lineage was closer to CXCR6− peripheral 
than CXCR6+ liver NK. These data reveal a large subset of human liver-resident T-betloEomeshi NK, 
distinguished by their surface expression of CXCR6, adapted for hepatic tolerance and inducible anti-
viral immunity.
The liver has a highly specialised immunological composition, enriched for a number of innate effector cells. NK 
cells are the most prevalent cell type amongst human intrahepatic leukocytes, accounting for around 30–40% 
of the total1. Accumulating data have underscored the key role that this large population can play in balancing 
hepatic tolerance and immunity2. In the hepatitis B virus (HBV)-infected liver they maintain cytotoxic capacity 
but have impaired non-cytolytic function, with reduced capacity to produce IFNγ 3. We previously demonstrated 
that liver NK cells can upregulate the death ligand TRAIL, giving them the capacity to kill hepatocytes that 
express the death-inducing receptor TRAIL-R2 in chronic hepatitis B (CHB), thereby mediating an antiviral effect 
at the expense of liver damage3,4. Unlike in the mouse, human NK cells express minimal TRAIL in the healthy 
liver but can be triggered to express it by endogenous4 or therapeutic5 IFNα . An IFN-induced expansion of 
TRAIL-expressing NK cells with the potential to kill infected hepatocytes was likewise demonstrated in another 
hepatotropic viral infection, hepatitis C6,7. In addition to this important role in killing virally infected hepatocytes 
and driving viral hepatitis, we recently showed that liver NK cells have the capacity to regulate antiviral T cells8. In 
line with emerging data for a role for NK cells as rheostats modulating T cell immunopathology9,10, we reported 
that NK cells in patients with CHB can selectively kill HBV-specific T cells. This was partially mediated through 
the TRAIL pathway, with a high frequency of intrahepatic HBV-specific T cells expressing the TRAIL-R2 death 
receptor not normally seen on T cells8. In addition, NK cells may limit liver fibrosis by interacting with and killing 
hepatic stellate cells through a number of receptor ligand pairs including TRAIL11. Thus diverse protective and 
pathogenic roles are emerging for liver NK cells, emphasizing the importance of understanding more about their 
origin and diversity.
Exciting progress has been made recently in our understanding of subsets of NK cells present within the 
mouse liver, with the demonstration of a CXCR6 expressing liver NK cell population capable of mediating recall 
responses to previously encountered pathogens or haptens12,13. Further work has revealed that a subset of murine 
liver NK cells constitute a separate lineage to the classical bone marrow-derived NK cells. DX5− TRAIL+ murine 
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liver NK cells expressing CD49a and CXCR6 were found to have a transcriptional profile distinct from the other 
DX5+ TRAIL– subset in the liver13–15. The DX5− CD49a+ subset was shown to be liver-resident using parabi-
osis experiments, whereas the remaining DX5+ CD49a− liver NK cells were exchanged between parabionts13. 
Further experiments revealed that the liver-resident NK cell subset was not derived from bone-marrow pre-
cursors like conventional NK cells, but could instead originate from hepatic progenitor cells, in line with their 
dominance in the fetal liver13. Differential dependence on transcription factors of these two murine liver NK 
cell subsets confirmed their distinct lineages14,15; in Eomes knockout mice the development of conventional NK 
cells in liver and spleen was markedly reduced whereas the liver-resident DX5− TRAIL+ population was not 
affected. T-bet knockout mice on the other hand, had a preferential reduction in DX5− TRAIL+ CXCR6+ liver 
NK cells. Ectopic expression of T-bet in liver progenitors repressed Eomes expression and forced the development 
of Eomes– liver-resident NK cells.
Here we therefore interrogated human liver NK cells to see if, as in murine studies, we could distinguish a 
liver-resident subset with a unique transcription factor profile.
Results and Discussion
CXCR6+ NK cells are enriched in the healthy and diseased human liver. To study the composition 
of the NK cell compartment in human liver we took advantage of access to the following valuable collection of 
samples: pre-implant biopsies and perfusion liquid from cadaveric donor livers prior to transplantation, resection 
tissue from healthy liver surrounding colorectal metastases, and biopsies with paired blood from patients with 
CHB. NK cells in periphery or intrahepatic leukocytes (IHL) were identified by the gating strategy shown in 
Fig. 1a; in brief, after exclusion of cell aggregates, gating on lymphocytes and subsequent exclusion of dead cells, 
CD14+ and CD19+ cells, NK cells were identified as CD3− CD56+ .
Figure 1. CXCR6+ NK cells are enriched in the liver in health and disease. (a) Gating strategy for 
identification of NK cells (singlets, live cells, CD14− , CD19− , CD3− , CD56+ cells) using multicolor flow 
cytometry and representative histograms of CXCR6 staining of NK cells from periphery and liver. (b) Summary 
frequencies of CXCR6+ NK cells from PBMC (n = 20), and liver (n = 15), comprising biopsies obtained from 
healthy donor livers (n = 10) or healthy margins of resections for colorectal metastases (n = 5). (c) Direct 
comparison of CXCR6 frequencies of NK cells isolated from perfusion liquid and liver tissue from the same 
healthy controls (n = 9). (d) Summary of CXCR6 frequencies of NK cells from paired PBMC and liver biopsies 
from patients with CHB (n = 30). (e) Summary of CXCR6 expression on NK cells from healthy liver (n = 15), 
compared to liver tissue from patients with CHB (n = 30). CHB patients were additionally divided by ALT 
(low ALT < 35 IU/l, n = 15; high ALT > 35 IU/l, n = 15). Diagrams show individual data for healthy controls 
and CHB. P-values indicated in each diagram. Mann-Whitney U-test (b), Kruskal-Wallis with Dunn’s multiple 
comparison test (e) and paired Wilcoxon test (c,d) were applied. ****p-value < 0.0001.
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Figure 2. Intrahepatic CXCR6+ NK cells have an immature phenotype and express high levels of CD69. 
(a) Representative contour plots for identification of CD56bright and CD56dim NK cells based on CD16/CD56 
expression within intrahepatic CXCR6− and CXCR6+ NK cells. Summary of frequency of CD56bright NK 
cells in intrahepatic CXCR6− and CXCR6+ NK cells of liver tissue of healthy controls (n = 15) and patients 
with CHB (n = 30). (b) Representative histogram overlay of CD57 expression on intrahepatic CXCR6− and 
CXCR6+ NK cells. Summary of frequency of CD57 expressing intrahepatic CXCR6− and CXCR6+ NK cells of 
healthy controls (perfusion liquid n = 6; liver tissue n = 1) and patients with CHB (n = 18). (c) Representative 
histogram overlaying CD69 expression on intrahepatic CXCR6− and CXCR6+ NK cells. Summary of 
frequency of CD69 expressing intrahepatic CXCR6− and CXCR6+ NK cells of healthy controls (fresh 
perfusion liquid n = 2; frozen perfusion liquid n = 6; liver tissue n = 4) and of patients with CHB (n = 7). (d) 
Representative histogram overlaying HLA-DR expression on intrahepatic CXCR6− and CXCR6+ NK cells. 
Summary of frequency of HLA-DR expressing intrahepatic CXCR6− and CXCR6+ NK cells of healthy controls 
(fresh perfusion liquid n = 2; frozen perfusion liquid n = 6; liver tissue n = 4) and patients with CHB (n = 7). 
Paired Wilcoxon test was applied for all figures. *p-value < 0.05, ***p-value < 0.001, ****p-value < 0.0001.
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Figure 3. Functional capacity of CXCR6− and CXCR6+ intrahepatic NK cells. (a) Summary of percentage 
of NK cells isolated from perfusates expressing CXCR6 with or without stimulation with IL-12/IL-18 (5 ng/ml, 
50 ng/ml) or PMA and Ionomycin at low (3 ng/ml, 100 ng/ml) or high (25 ng/ml, 1 μ g/ml) dose (n = 7; 7; 7; 5). 
(b) Representative histograms overlaying IFNγ production of unstimulated, and high dose PMA/Ionomycin 
stimulated, for intrahepatic CXCR6− and CXCR6+ NK cells. Summary of IFNγ production by CXCR6− and 
CXCR6+ NK cells from healthy liver perfusates with stimuli as indicated (n = 7; 7; 5), after subtraction of 
the unstimulated control. (c) Representative histograms overlaying TNF, MIP-1β and GM-CSF production 
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Intrahepatic NK cells were highly enriched for the expression of the surface chemokine receptor CXCR6, 
which was only found on a small proportion of peripheral NK cells (Fig. 1a,b). Paired perfusion liquid and 
pre-implant biopsies obtained from the same cadaveric donor livers had similarly high frequencies of CXCR6+ 
NK cells (Fig. 1c). CXCR6+ NK cells are therefore present within the liver vasculature, compatible with the 
reported expression of the ligand CXCL16 by liver sinusoidal populations16,17. Sampling of a cohort of patients 
with CHB, from whom we had the opportunity to obtain paired blood and intrahepatic samples, similarly 
showed a striking selective increase in CXCR6+ NK cells within the hepatic compartment in all cases (mean 
56%, Fig. 1d). The enrichment of CXCR6 expressing NK cells seen in the healthy liver was therefore maintained 
in diseased livers, even in the presence of HBV-related liver inflammation (measured by alanine transaminase, 
ALT, Fig. 1e), which is characterised by a large lymphocytic infiltrate18.
Thus we describe a surface marker defining a subset of NK cells that is markedly enriched in the liver of 
healthy donors, and maintained at similarly high frequencies in patients with a variable degree of HBV-related 
liver inflammation. The proportion of CXCR6+ NK cells varied widely amongst both healthy and HBV-infected 
livers. The drivers of this variation in CXCR6+ NK cell hepatic accumulation remain to be determined; their 
frequency could not be attributed to any of the factors we examined (age, CMV serostatus; in CHB cohort: HBV 
viraemia, eAg status, ALT).
CXCR6+ liver NK cells have an immature, tissue-resident phenotype. We then compared the 
surface marker expression of CXCR6+ and CXCR6− fractions of intrahepatic NK cells to better define their 
characteristics. CXCR6+ NK cells in the healthy human liver were predominantly CD56brightCD16low/intermediate, 
whereas the CXCR6− subset was largely CD56dimCD16+ (Fig. 2a). In the HBV-infected liver, CXCR6+ NK 
cells remained enriched for the immature markers CD56brightCD16low/intermediate (compared to the CXCR6− sub-
set), although to a more variable degree than in the healthy liver (Fig. 2a). CXCR6+ NK cells in the liver con-
sistently lacked expression of CD57 (Fig. 2b), a marker that has been associated with NK cell maturity/antigen 
exposure19,20. All CD57+ staining on NK cells in healthy or diseased liver segregated with the CXCR6− subset 
(Fig. 2b). This is concordant with findings in the murine liver, where the liver-resident population of DX5− NK 
cells has a more immature phenotype13,15.
Expression of CD69 has recently been described to be a distinguishing feature of human tissue-resident mem-
ory T cells21, inhibiting sphingosine-1-phosphate (S1P1) receptor function to regulate peripheral T cell reten-
tion22–24; we therefore examined its expression on liver NK cells. In line with the concept that the CXCR6+ NK 
cells may be liver-resident, 95% co-expressed CD69 directly ex vivo (Fig. 2c). Although commonly used as a 
marker of activation, in this setting CD69 was more likely reflective of tissue residency, since CXCR6+ NK cells 
were not similarly enriched for other markers of activation such as HLA-DR (Fig. 2d).
CXCR6 marks a subset of hepatic NK cells functionally adapted to the liver niche. To exam-
ine their effector function, liver-infiltrating lymphocytes from perfusates of healthy livers were stimulated with 
IL-12/IL-18 or PMA/ionomycin, since negligible cytokine production was observed ex vivo. Short-term stimuli 
(4 hours) did not alter surface CXCR6 expression (Fig. 3a). Although strong stimulation with low or high-dose 
PMA/ionomycin induced a large and variable percentage of both CXCR6+ and CXCR6− fractions to produce 
IFNγ , the more physiological stimulus of IL-12/IL-18 induced less IFNγ from the CXCR6+ than the CXCR6− 
fraction (Fig. 3b). Additional pro-inflammatory cytokines/chemokines TNF and MIP-1β also tended to be pro-
duced by lower percentages of CXCR6+ than CXCR6− intrahepatic NK cells following low or high-dose PMA/
ionomycin, whilst GM-CSF production showed no clear difference (Fig. 3c; IL-12/IL-18 failed to elicit these 
cytokines). CXRC6+ intrahepatic NK cells were more likely to degranulate upon PMA/ionomycin stimulation 
than their CXCR6− counterparts (Fig. 3d); however ex vivo granzyme B and perforin levels revealed that the 
CXCR6+ fraction have strikingly less constitutive cytotoxic capacity (Fig. 3e,f).
NK cells can also mediate perforin-independent cytotoxicity, which is likely to be particularly relevant in the 
liver since hepatocytes are relatively resistant to perforin/granzyme cytotoxicity2. Cytotoxicity through death 
ligands such as TRAIL has been shown to be critical for liver damage in several murine models as well as HBV 
and HCV2. Murine liver-resident NK cells (DX5− ) express high levels of TRAIL25 whereas NK cells express 
negligible TRAIL in the healthy human liver26. In contrast, in HBV-related liver inflammation we have described 
of unstimulated, and high dose PMA/Ionomycin stimulated, intrahepatic CXCR6− and CXCR6+ NK cells. 
Summary of TNF, MIP-1β and GM-CSF production by CXCR6− and CXCR6+ NK cells from healthy liver 
perfusates with stimuli as indicated (n = 7; 5), after subtraction of the unstimulated control. (d) Representative 
histograms overlaying CD107a expression of unstimulated, and high dose PMA/Ionomycin stimulated, 
intrahepatic CXCR6− and CXCR6+ NK cells. Summary of CD107a expression by CXCR6− and CXCR6+ 
NK cells from healthy liver perfusates with stimuli as indicated (n = 7; 5), after subtraction of the unstimulated 
control. (e) Representative histogram overlaying ex vivo granzyme B expression in intrahepatic CXCR6− and 
CXCR6+ NK cells. Summary of frequency of granzyme B expressing intrahepatic CXCR6− and CXCR6+ NK 
cells from healthy controls (perfusion liquid n = 9; liver tissue n = 1). (f) Representative histogram overlaying 
ex vivo perforin expression in intrahepatic CXCR6− and CXCR6+ NK cells. Summary of frequency of perforin 
expressing intrahepatic CXCR6− and CXCR6+ NK cells from healthy controls (perfusion liquid n = 7). (g) 
Representative histogram overlaying TRAIL expression on intrahepatic CXCR6− and CXCR6+ NK cells from 
a patient with CHB. Summary of frequency of TRAIL expressing intrahepatic CXCR6− and CXCR6+ NK 
cells from patients with CHB (n = 10). Kruskal-Wallis with Dunn’s multiple comparison test (A) and Paired 
Wilcoxon test (B–G) was applied. *p-value < 0.05, ***p-value < 0.001.
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Figure 4. The liver contains a distinct T-betloEomeshi NK cell subset identified by CXCR6, but not CD49a 
expression. (a) Representative contour plots for identification of T-bethiEomeslo and T-betloEomeshi subsets 
of total NK cells from periphery and liver tissue. (b) Summary of frequency of T-betloEomeshi cells of total 
NK cells in PBMC (n = 20) and liver tissue of healthy controls (n = 10), and paired PBMC and liver biopsies 
from patients with CHB (n = 19). (c) Representative contour plots for identification of T-betloEomeshi and 
T-bethiEomeslo subsets in intrahepatic CXCR6− and CXCR6+  NK cells. (d) Summary of frequency of 
T-betloEomeshi cells among intrahepatic CXCR6− and CXCR6+ NK cells of liver tissue of healthy controls 
(n = 10) and patients with CHB (n = 19). (e,f) Correlation of frequency of T-betloEomeshi and CXCR6 
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an expansion of TRAIL-expressing NK cells that make an important contribution to disease pathogenesis4,8. 
Co-staining NK cells from HBV-infected livers with CXCR6 and TRAIL established that TRAIL induction was 
largely restricted to the CXCR6+ fraction (Fig. 3g).
The liver contains a distinct T-betlo Eomeshi NK cell subset identified by CXCR6. Differential 
expression of the transcription factors T-bet and Eomes has been shown to instruct the development of distinct 
lineages of NK cells in mice, with murine liver-resident NK cells having a unique T-bethiEomeslo profile13–15. 
Instead in humans, peripheral NK cells have recently been reported to be predominantly T-bethiEomeslo 27, con-
firmed in the donors we sampled (Fig. 4a); however, a distinct profile of T-bet/Eomes usage for human liver NK 
cells has not been defined. We found that intrahepatic NK cells could be divided into two populations according 
to their expression of T-bet and Eomes; in addition to the T-bethiEomeslo staining characteristic of peripheral 
NK cells, a mean of 48% of hepatic NK cells had the converse T-betloEomeshi profile (Fig. 4a,b). The percent of 
T-betloEomeshi NK cells was similarly variable in healthy and HBV-infected livers, ranging from 5% to 88% per-
cent of total intrahepatic NK cells; in contrast, NK cells with this transcription factor profile were consistently 
barely detectable in the circulation of healthy donors or patients with CHB (Fig. 4b).
Further analysis revealed that the expression of CXCR6 on intrahepatic NK cells was a robust surface marker 
to predict their transcription factor profile. The majority of CXCR6+ liver NK cells were T-betloEomeshi, whereas 
liver NK cells lacking CXCR6 mostly had the converse pattern of T-bethiEomeslo, with a mean of only 4% being 
T-betloEomeshi (Fig. 4c,d). The link between surface CXCR6 and intranuclear Eomes was underscored by the 
very strong correlation between the percentage expression of these two markers for intrahepatic NK cells within 
healthy and HBV-infected livers (Fig. 4e,f). This capacity to dissect liver NK cells into discrete T-bethiEomeslo and 
T-betloEomeshi subsets was unique to CXCR6 and not a property of CD49a, another marker recently described 
to define a population of human liver NK cells28 (Fig. 4g,h). However we did confirm that CD49a+ NK cells 
were more enriched in liver parenchyma than liver vasculature (Fig. 4i), albeit at lower overall frequencies than 
CXCR6+ NK cells.
To further probe whether CXCR6 defined a population of liver-resident NK cells, we next examined the small 
fraction of circulating NK cells that expressed CXCR6. CXCR6+ peripheral NK cells had a transcription factor 
profile much more analogous to that of CXCR6− peripheral NK cells than to their CXCR6+ intrahepatic coun-
terparts. CXCR6+ peripheral NK cells were mainly T-bethiEomeslo like most peripheral NK cells (Fig. 4j,k), in 
contrast to the predominant T-betloEomeshi profile amongst the much larger fraction of CXCR6+ NK cells in 
the liver. The fact that the small population of CXCR6 expressing NK cells detectable in the periphery did not 
share their transcription factor usage with their liver counterparts, even in the dynamic situation of HBV-related 
liver inflammation, supports the concept of hepatic CXCR6+ NK cells being liver-resident. Liver CXCR6+ 
T-betloEomeshi NK cells could either be a separate lineage derived from hepatic progenitors13 and/or might be 
recruited from the periphery29 and acquire their liver-specific profile by in situ differentiation in response to local 
microenvironmental cues.
In conclusion, we demonstrate that CXCR6 dissects human liver NK cells into two discrete subsets. The 
CXCR6+ fraction displays a predominantly CD56brightCD16− CD57− phenotype, capable of expressing TRAIL 
in diseased liver, analogous to the DX5− TRAIL+ CXCR6+ liver-resident NK cell population in the mouse. We 
show that CXCR6 expression marks a novel, sizeable population of T-betloEomeshi NK cells within the human 
liver that are barely detectable in the periphery. The chemokine CXCL16, the ligand for CXCR6, is strongly 
expressed in the sinusoids of human liver16,17, providing a mechanism for hepatic retention of CXCR6 expressing 
lymphocytes. The uniform co-expression of CD69 by CXCR6+ NK cells may also confer tissue residency through 
its capacity to prevent lymphocyte egress by counteracting S1P123,24,30. Expression of CD69 is now well accepted as 
a marker of tissue-resident T cells21; our data reveal its applicability to denote resident NK cells.
The liver-resident CXCR6+ subset of NK cells is well-adapted to the tolerogenic liver niche, since in the 
healthy liver they have low expression of cytotoxic mediators and pro-inflammatory cytokines. However their 
capacity to express TRAIL in response to a pathogen challenge renders CXCR6+ T-betloEomeshi NK cells capable 
of regulating liver immunopathology in viral hepatitis by TRAIL-dependent interactions with hepatocytes and 
antiviral T cells2. We therefore propose that the population of CXCR6+ T-betloEomeshi NK cells residing in the 
human liver serves a key role as an inducible defence mechanism, eliminating infected or transformed cells and 
curtailing excessive T cell responses. In the setting of a persistent infection such as HBV, their homeostatic effects 
can become detrimental, contributing to liver pathology and preventing an adequate antiviral T cell response. 
expression of NK cells from liver tissue of healthy controls ((e) n = 10) and liver biopsies from patients with 
CHB ((f) n = 19). (g) Representative contour plots for identification of T-betloEomeshi and T-bethiEomeslo 
subsets among intrahepatic CD49a− and CD49a+ NK cells. (h) Summary of frequency of T-betlo Eomeshi cells 
among intrahepatic CD49a− and CD49a+ NK cells of healthy liver tissue (n = 8). (i) Summary of frequency 
of CD49a expression on intrahepatic NK cells from paired perfusion liquid and tissue from pre-implant donor 
livers (n = 7). (j) Representative contour plots for identification of T-betloEomeshi and T-bethiEomeslo subsets 
among peripheral CXCR6− and CXCR6+ NK cells. (k) Summary of frequency of T-betloEomeshi cells among 
peripheral CXCR6− and CXCR6+ NK cells (n = 20) and intrahepatic CXCR6+ NK cells of liver tissue of 
healthy controls (n = 10); and of peripheral CXCR6− and CXCR6+ NK cells and paired intrahepatic CXCR6+ 
NK cells of patients with CHB (n = 19). P-values and r indicated in each diagram. Mann-Whitney U-test 
((b) left), Kruskal-Wallis with Dunn’s multiple comparison test ((k) left), Friedmans with Dunn’s multiple 
comparision test ((k) right), paired Wilcoxon test ((b) right, (d,h,i)) and Spearman’s correlation (e,f) were 
applied. *p-value < 0.05, **p-value < 0.01, ****p-value < 0.0001.
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The capacity to distinguish this population of T-betloEomeshi NK cells by their surface expression of CXCR6 will 
expedite future studies to further explore their role in liver immunity and disease.
Methods
Patients and controls. This study was approved by the local ethical boards of the Central and North West 
London NHS Trust, The Royal London Hospital and The Royal Free Hospital, with all participants giving writ-
ten informed consent. Blood and paired surplus tissue from liver biopsies of patients with untreated CHB were 
obtained from the Royal London Hospital. Healthy margins of metastatic tumor resections of 5 patients were 
obtained from the Royal Free Hospital. Perfusion liquid of 18 liver transplantations, 9 with paired pre-implant 
liver biopsies (and one unpaired biopsy), taken from healthy cadaveric livers to be used for transplantation, 
were obtained from the Royal Free Hospital. Blood was taken from 20 healthy controls who were recruited at 
University College London. Experiments were carried out in accordance with approved guidelines. Demographic 
and clinical characteristics of donors are summarised in Table 1.
Sample preparation. PBMC were isolated from heparinized blood by density centrifugation using a stand-
ard Ficoll density centrifugation method. Liquid used to transport and perfuse healthy cadaveric livers prior to 
transplantation (perfusates) was centrifuged to concentrate the volume, before Ficoll density isolation of liver 
intravascular leukocytes. To obtain intrahepatic leukocytes from liver tissue, biopsy or resection fragments were 
mechanically dissociated before passing through a 70 μ m cell strainer. Intrahepatic leukocytes isolated from liver 
biopsies were used immediately whereas those isolated from larger liver tissue were isolated with an extra Percoll 
density centrifugation step before experimentation.
Antibodies used for characterization of intrahepatic NK cells. The following anti-human anti-
bodies were used in this study: anti-CD3-BV605 (clone OKT3, Biolegend), anti-CD3-BUV395 (clone UCHT1, 
BD Bioscience), anti-CD14-V500 (clone M5E2, BD Bioscience), anti-CD19-BV510 (clone SJ25C1, BD 
Bioscience), anti-CD56-PE-Cy7 (clone NCAM16.2, BD Bioscience), anti-CXCR6-PE or anti-CXCR6-APC 
(clone K041E5, Biolegend), anti-CD57-AF488 (clone TB01, eBioscience), anti-TRAIL-BV421 (clone RIK-
2, BD Bioscience), anti-CD49a-FITC (clone TS2/7, Biolegend), anti-HLA-DR V500 (clone G46-6, BD 
Bioscience) and anti-CD69-PE-Dazzle (clone FN50, Biolegend) for surface antigens; and anti-T-bet-eFlour610 
(clone 4B10, eBioscience) and anti-Eomes-PE-eFlour610 (clone Dan11mag, eBioscience) for intranuclear 
antigens; anti-IFNγ -V450 (BD Bioscience), anti-MIP-1β -PerCP-Cy5.5 (cloneD21–1351, BD Bioscience), 
anti-GM-CSF-PE-CF594 (clone BVD2–21C11, BD Bioscience), anti-TNF-FITC (clone MAb11, BD Bioscience), 
anti-Granzyme B-AlexaFlour700 (clone GB11, BD Bioscience) and anti-Perforin-PerCP-Cy5.5 (clone dG9, 
Biolegend) for intracellular antigens.
Flow cytometric analysis. PBMC and IHL were washed with PBS before staining with live/dead fixa-
ble dye (Invitrogen) at 4 °C for 10 min in the dark. Cells were subsequently washed with PBS before blocking 
Fc-Receptors using saturating concentrations of FcR blocking reagent (Miltenyi) at 4 °C in the dark. Antibodies 
used for surface staining were added after 10 min to the samples and incubated at 4 °C in the dark for another 
30 min. Cells were then washed and fixed with BD Cytofix (BD Bioscience) for 20 min at 4 °C in the dark for 
samples used for the analysis of surface marker expression or with Buffer A of the BD FoxP3 Buffer Set (BD 
Bioscience) for 10 min at room temperature (RT) in the dark to enable analysis of the intranuclear transcrip-
tion factor expression, or with BD Cytofix/Cytoperm buffer for analysis of intracellular cytokines. Once fixed, 
cells used for analysis of transcription factor expression were incubated in buffer C of the BD FoxP3 Buffer Set 
according to the manufacturer’s instructions, prior to the addition of the anti-T-bet and anti-Eomes antibodies 
for 30 min at RT in the dark. Finally, cells were washed twice with PBS. After fixation and permeabilization of cells 
Healthy PBMC 
(n = 20)
Healthy liver 
(n = 24)
CHB (PBMC/
liver) (n = 30)
Age (years) Media (range) 31 (20–40) 44 (16–69) 34 (23–59)
Sex
Female 14 5 9
Male 6 8 21
Unknown – 11
Ethnicity
Afro-Caribbean – – 9
Arab 1 – –
Asian 1 3 10
Caucasian 16 9 5
South-Asian 2 – 6
Unknown – 12 –
ALT (IU/L) Median (range) n.a. n.a. 35 (10–452)
HBV-DNA (IU/ml) Median (range) n.a. n.a. 11631 (BLQ - 9.8 × 108)
HBeAg+ n.a. n.a. 8
Table 1.  Characteristics of healthy controls and patients from whom PBMC and liver tissue were obtained. 
n.a. non applicable. BLQ below limit of quantification.
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used for detection of intracellular antigens, cells were washed in PBS containing 1% FBS 0.1% saponin (Sigma) 
prior to addition of antibodies targeting intracellular antigens mentioned above for 30 min at 4 °C in the dark. 
After a final wash with saponin containing buffer cells were resuspended in PBS. All samples were acquired on a 
BD LSRII using BD FACSDiva8.0 (BD Bioscience) and data analysed using FlowJo 8 (TreeStar).
Stimulation of intrahepatic cells. Frozen perfusate cells were thawed, washed and incubated in 
RPMI + 10% FCS in the presence of 10 U/ml DNAse (Roche) for 45 min at 37 °C. After washing, cells were cul-
tured with either 5 ng/ml IL-12 and 50 ng/ml IL-18 (both R&D), 3 ng/ml PMA and 100 ng/ml Ionomycin (both 
Sigma, low PMA+ Ionomycin) or 25 ng/ml PMA and 1 μ g/ml Ionomycin for 4 h at 37 C. Anti-CD107a-APC 
(clone H4A3, BD Bioscience) was present during culture. Brefeldin A (Sigma) and Monensin (BD Bioscience) 
were added for the last 3 h of stimulation.
Sample analysis. Data are presented as individual data points with the mean indicated for each group. Prism 
5 (GraphPad Software) was used for all statistical analysis as follows: the Mann-Whitney U-test was used to 
compare two unpaired sample groups, the Wilcoxon-test was used to compare two paired groups, Friedmans 
with Dunn’s multiple comparision test was used to compare three paired samples groups and Kruskal-Wallis with 
Dunn’s multiple comparison test was used to compare three unpaired sample groups. Spearman’s correlation was 
used for the correlation of frequency of T-betloEomeshi and CXCR6 expression. *p-value < 0.05, **p-value < 0.01, 
***p-value < 0.001, ****p-value < 0.0001.
References
1. Doherty, D. G. et al. The human liver contains multiple populations of NK cells, T cells, and CD3+ CD56+ natural T cells with 
distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. J Immunol 163, 2314–2321 (1999).
2. Maini, M. K. & Peppa, D. NK cells: a double-edged sword in chronic hepatitis B virus infection. Front Immunol 4, 57, doi: 10.3389/
fimmu.2013.00057 (2013).
3. Peppa, D. et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. 
PLos Pathog 6, e1001227, doi: 10.1371/journal.ppat.1001227 (2010).
4. Dunn, C. et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. 
J Exp Med 204, 667–680, doi: 10.1084/jem.20061287 (2007).
5. Micco, L. et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic 
hepatitis B. J Hepatol 58, 225–233, doi: 10.1016/j.jhep.2012.09.029 (2013).
6. Ahlenstiel, G. et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent 
manner. Gastroenterology 138, 325–335 e321–322, doi: 10.1053/j.gastro.2009.08.066 (2010).
7. Stegmann, K. A. et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. 
Gastroenterology 138, 1885–1897, doi: 10.1053/j.gastro.2010.01.051 (2010).
8. Peppa, D. et al. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med 210, 
99–114, doi: 10.1084/jem.20121172 (2013).
9. Crome, S. Q., Lang, P. A., Lang, K. S. & Ohashi, P. S. Natural killer cells regulate diverse T cell responses. Trends Immunol 34, 
342–349, doi: 10.1016/j.it.2013.03.002 (2013).
10. Welsh, R. M. & Waggoner, S. N. NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. Virology 435, 
37–45, doi: 10.1016/j.virol.2012.10.005 (2013).
11. Glassner, A. et al. NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells 
in a TRAIL-, FasL- and NKG2D-dependent manner. Lab Invest 92, 967–977, doi: 10.1038/labinvest.2012.54 (2012).
12. Paust, S. et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. 
Nat Immunol 11, 1127–1135, doi: 10.1038/ni.1953 (2010).
13. Peng, H. et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J Clin Invest 123, 1444–1456, doi: 
10.1172/JCI66381 (2013).
14. Daussy, C. et al. T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone 
marrow. J Exp Med 211, 563–577, doi: 10.1084/jem.20131560 (2014).
15. Sojka, D. K. et al. Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. 
eLife 3, e01659, doi: 10.7554/eLife.01659 (2014).
16. Heydtmann, M. et al. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to 
cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 174, 1055–1062, doi: 10.4049/jimmunol.174.2.1055 
(2005).
17. Wehr, A. et al. Chemokine receptor CXCR6− dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. 
J Immunol 190, 5226–5236, doi: 10.4049/jimmunol.1202909 (2013).
18. Maini, M. K. et al. The role of virus-specific CD8(+ ) cells in liver damage and viral control during persistent hepatitis B virus 
infection. J Exp Med 191, 1269–1280, doi: 10.1084/jem.191.8.1269 (2000).
19. Bjorkstrom, N. K. et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation 
uncoupled from NK-cell education. Blood 116, 3853–3864, doi: 10.1182/blood-2010-04-281675 (2010).
20. Lopez-Verges, S. et al. Expansion of a unique CD57(+ ) NKG2Chi natural killer cell subset during acute human cytomegalovirus 
infection. P Natl Acad Sci USA 108, 14725–14732, doi: 10.1073/pnas.1110900108 (2011).
21. Sathaliyawala, T. et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. 
Immunity 38, 187–197, doi: 10.1016/j.immuni.2012.09.020 (2013).
22. Mackay, L. K. et al. The developmental pathway for CD103(+ )CD8+ tissue-resident memory T cells of skin. Nat Immunol 14, 
1294–1301, doi: 10.1038/ni.2744 (2013).
23. Shiow, L. R. et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. 
Nature 440, 540–544, doi: 10.1038/nature04606 (2006).
24. Skon, C. N. et al. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. Nat 
Immunol 14, 1285–1293, doi: 10.1038/ni.2745 (2013).
25. Gordon, S. M. et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 
36, 55–67, doi: 10.1016/j.immuni.2011.11.016 (2012).
26. Ishiyama, K. et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in 
humans. Hepatology 43, 362–372, doi: 10.1002/hep.21035 (2006).
27. Knox, J. J., Cosma, G. L., Betts, M. R. & McLane, L. M. Characterization of T-bet and eomes in peripheral human immune cells. 
Front Immunol 5, 217, doi: 10.3389/fimmu.2014.00217 (2014).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:26157 | DOI: 10.1038/srep26157
28. Marquardt, N. et al. Cutting edge: identification and characterization of human intrahepatic CD49a+ NK cells. J Immunol 194, 
2467–2471, doi: 10.4049/jimmunol.1402756 (2015).
29. Moroso, V. et al. NK cells can generate from precursors in the adult human liver. Eur Journal Immunol 41, 3340–3350, doi: 10.1002/
eji.201141760 (2011).
30. Mackay, L. K. et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell 
retention. J Immunol 194, 2059–2063, doi: 10.4049/jimmunol.1402256 (2015).
Acknowledgements
We thank all the patients and staff who generously helped with samples for the study, Richard Milne and the 
Department of Virology at the Royal Free for CMV serology and Eleanor Riley for valuable discussions. This work 
was funded by a Wellcome Trust Investigator Award to MKM funding KS and LP, MRC Career Development 
Award to CD, MRC Clinical Research Training Fellowship to DP, Wellcome Trust Henry Dale Fellowship to VM.
Author Contributions
K.A.S., C.D. and M.K.M. designed experiments, K.A.S., C.P., T.C., L.J.P. and D.P. conducted experiments, F.R., 
N.H., U.G., G.F., V.M., B.R.D., P.K. and M.K.M. provided patient samples, K.A.S., F.R., N.H., U.G., V.M. and 
M.K.M. analysed laboratory and/or clinical data; K.S. and M.K.M. wrote the manuscript, all other authors 
critically reviewed the manuscript.
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Stegmann, K. A. et al. CXCR6 marks a novel subset of T-betloEomeshi natural killer cells 
residing in human liver. Sci. Rep. 6, 26157; doi: 10.1038/srep26157 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
